Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

35 results about "Once daily dosing" patented technology

Progestogen-free oral dosage unit for use in female contraception and treatment of endometriosis

The invention relates to an oral dosage unit for use in a method of contraception in a mammalian female or for use in a method of treating endometriosis in a mammalian female, said oral dosage unit containing GnRH antagonist, estrogen and no progestogen; and wherein said method comprises once daily oral administration to the mammalian female of the oral dosage unit during a period of at least 28 days.
Owner:PANDORA ENDOCRINE INNOVATION BV

Formulations of apremilast

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).
Owner:AMGEN INC

Formulation for lacosamide

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.
Owner:SHANGHAI AUCTA PHARMA CO LTD

Improved GIP receptor agonist peptide compounds and uses thereof

The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and / or prevention of emesis, or a symptom or condition associated with emesis while having an improved profile.
Owner:TAKEDA PHARMA CO LTD

Next generation riluzole prodrugs

A pharmaceutical composition includes about 100 mg to about 280 mg of troriluzole, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the salt, wherein the pharmaceutical composition is in a once-a-day oral dosage form, which provides an AUC0-inf for riluzole of about 80% to about 125% of about 791 h•ng / mL to about 2330 h•ng / mL. A method of treating a disease or a condition in a patient in need thereof includes administering to the patient once daily the pharmaceutical composition.
Owner:BIOHAVEN THERAPEUTICS LTD

Dosing regimen of GLP-1

To provide dosing regimens of GLP-1 analogs for the treatment of fat, obese, overweight, nonalcoholic fatty liver disease (NAFLD), and / or nonalcoholic steatohepatitis (NASH).SOLUTION: Administering to the subject a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs; A dosing regimen is provided, comprising: a first effective amount administered continuously, or intermittently at an interval between two consecutive administrations of six hours or less; and one or more second active ingredients selected from the group consisting of a second effective amount of GLP-I and a GLP-1 analog, administered to said subject once daily, twice daily, three times daily, or four times daily.SELECTED DRAWING: None
Owner:SHANGHAI BENEMAE PHARMACEUTICAL CORP

Pharmaceutical composition for treating glaucoma and application thereof

According to the pharmaceutical composition for treating glaucoma and intraocular hypertension provided by the invention, the stability of the pharmaceutical composition is obviously improved through a salt changing technology; the pharmaceutical composition is prepared from netasdil free alkali or a pharmaceutically acceptable salt thereof, timolol free alkali or a pharmaceutically acceptable salt thereof, and dorzolamide free alkali or a pharmaceutically acceptable salt thereof. The pharmaceutical composition has excellent stability when the pH value is 4.5-5.4. According to the present invention, the effective dose of the pharmaceutical composition is applied to the eyes of the patient requiring the intraocular pressure at the sleeping time or at the time close to the sleeping time once a day, such that the intraocular pressure can be efficiently and rapidly reduced so as to maintain the intraocular pressure in the physiological range for a long time, the side effect is small, and the patient compliance is high.
Owner:SHENYANG PHARMA UNIV

Hydroxyprogesterone caproate compositions and methods of use in preventing preterm birth - Patents.com

SOLUTION: HPC compositions and methods of treatment for preventing PTB and improving neonatal outcomes. The invention provides dosing regimens beginning as early as 14 weeks of fetal gestation and as long as 25 weeks. The invention provides high levels of exogenous progesterone at a time when endogenous progesterone is most needed. The invention consistently achieves activity levels of HPC that achieve efficacy. An exemplary dosing regimen consists of oral administration of HPC in the range of 1200 mg to 1600 mg, with the HPC administered in a once-daily, twice-daily, or three-times-daily dose.
Owner:LIPOCINE INC

Formulations of apremilast

ActiveTWI944002BDiseaseSuccinic acid
This document provides oral dosage forms comprising a) a tablet core comprising (i) a drug layer comprising apremilast and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) an expandable layer comprising one or more expandable polymers; and b) a coating layer disposed on the tablet core, wherein the surface of the oral dosage form includes at least one drug release pore. The disclosed oral dosage forms provide once-daily administration of apremilast and are suitable for treating diseases or disorders alleviated by inhibition of phosphodiesterase IV subtype (PDE4).
Owner:AMGEN INC

Sustained-release formulations of colchicine and methods of using same

ActiveUS12691072B1Immediate releaseColchicine
Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and / or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
Owner:MURRAY & POOLE ENTERPRISES LTD

Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.
Owner:AUSPEX PHARMA INC

Methods of treating a neurodegenerative disease

PCT designated stageWO2026088136A1Organic active ingredientsNervous disorderCaplet Dosage FormPhosphorylation
The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.
Owner:ARIBIO CO LTD

Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy

PCT designated stageWO2025242589A1Organic active ingredientsGranular deliveryDiseaseDeferasirox
The invention relates to a pharmaceutical dosage form filled with formulations for once-a-day oral administration of deferiprone and deferasirox. Both formulations are in form of coated pellets or coated minitablets. The invention is directed to the claimed pharmaceutical dosage form for use in the treatment of diseases which cause an overload of iron.
Owner:CHIESI FARMACEUTICI SPA

Compositions for treating vaginal candida (biofilm) infections with improved relapse prevention

PCT designated stageWO2026027529A1Aerosol deliveryOintment deliveryMicronazoleReference product
The present invention provides a topical pharmaceutical formulation comprising a combination of miconazole or a pharmaceutically acceptable salt thereof and domiphen bromide, a formulation vehicle and a viscosity modifier; wherein the ratio of w / w% miconazole (salt) to w / w% domiphen bromide is between 6 to 20 endpoints included and wherein the amount of viscosity modifier is sufficient to adjust the viscosity of the topical formulation to a value of 1000-4600 mPa.s measured at 25°C. The invention further provides use of said formulation in a treatment of vaginal Candida (biofilm) infections, wherein once daily use of 4.5-5.5 g of the formulation for a duration of 7 days performed better than a reference product and unexpectedly also performed better than a formulation with a double domiphen bromide dose. Improved performance was the relapse prevention for a duration of at least 28 days in human patients treated for a vulvovaginal Candida (biofilm) infection.
Owner:FHP BV

A 30 mg bilayer biphasic release tablet containing meloxicam or a pharmaceutically acceptable salt thereof and a process for its preparation

PendingCN122297415AMeloxicamDrug content
This invention relates to a 30 mg bilayer biphasic-release tablet containing merogabarine or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The tablet is a bilayer tablet consisting of an immediate-release layer and a sustained-release layer, wherein the immediate-release layer accounts for 20%–35% of the total drug content, and the sustained-release layer accounts for 65%–80% of the total drug content. The sustained-release layer contains hydroxypropyl methylcellulose K15M or hydroxypropyl methylcellulose K100M and ethylcellulose. Under the conditions of the second method for release determination in the current edition of the Chinese Pharmacopoeia, the tablet has a predetermined 24-hour release window in any of the media selected from pH 1.2, pH 4.5, and pH 6.8, and maintains a small difference in media values ​​at 8 hours and 12 hours, making it suitable for development into an oral sustained-release formulation for once-daily administration.
Owner:BEIJING DONGXURI PHARM TECH CO LTD

Use of Bruton's tyrosine kinase (Btk) inhibitors

The present invention provides a pharmaceutical composition for use in the treatment of follicular lymphoma. [Solution] The pharmaceutical composition comprises 560 mg of a BTK inhibitor and is formulated for a continuous once-daily dosing regimen, and the BTK inhibitor is as follows: JPEG2026065005000042.jpg6042 A pharmaceutical composition having the following structure is provided.
Owner:PHARMACYCLICS LLC

Modulated release pharmaceutical formulations comprising deferiprone

The present invention relates to a pharmaceutical composition for oral administration comprising deferiprone. In particular, the present invention also relates to a delayed release tablet suitable for twice daily administration or once daily administration. The invention also relates to methods of making and using such tablets.
Owner:CHIESI FARMACEUTICI SPA

Method for treating cancer with oral dosage form of estrogen receptor-alpha inhibitor

To provide pharmaceutical compositions comprising an inhibitor of human ERα, and methods of cancer therapy using the ERα inhibitor.SOLUTION: The present invention provides an oral dosage form comprising i) (E)-NN-dimethyl-4-[2-[5-[(Z)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]but-2-enamide or a pharmaceutically acceptable salt thereof, and ii) at least one pharmaceutically acceptable excipient, wherein the oral dosage form, when administered orally once daily to a human subject, is formulated to achieve a mean Cmx of about 1 ng / mL to about 4 ng / mL as measured for every mg of formula (I) in the dosage form.SELECTED DRAWING: None
Owner:EISAI R&D MANAGEMENT CO LTD

Gastroretentive dosage forms comprising deuterated tetrabenazine

Provided herein are controlled release gastroretentive dosage forms containing deuterated tetrabenazine for use in the treatment of e.g. Hyperactivity dyskinesia. The dosage form provides advantageous pharmacokinetic profiles when orally administered to a subject once a day.
Owner:OSPEX PHARMACEUTICALS LLC

Pharmaceutical compositions for minocycline

The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
Owner:DR REDDYS LAB LTD

Multiparticulate dosage forms comprising deutetrabenazine

PendingUS20240374528A1Organic active ingredientsNervous disorderDeutetrabenazineMotor disorder
Provided herein are modified release multiparticulate dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. The dosage forms are easily administered to a subject on a once-daily or twice daily basis, and provide a safe and effective pharmacokinetic profile.
Owner:AUSPEX PHARMA INC

Methods of treatment using dry powder compositions of treprostinil prodrugs

The present disclosure provides methods for treating pulmonary hypertension (PH) in a patient in need thereof, comprising administering via a dry powder inhaler (DPI) to the patient, during an administration period, a compound of Formula (I), (I), or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, wherein R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. In embodiments, during the administration period, the compound of Formula (I), or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, is administered at a starting dose comprising about 80 μg to 160 μg once daily in a single dosing session, and the starting dose is titrated during the titration period to a maximum tolerated dose (MTD) of about 1280 µg or less. In embodiments, the administration period comprises a maintenance period, and the MTD is administered to the patient during the maintenance period. In embodiments, during the administration period, a dose of about 700-1300 µg of the compound of Formula (I), or enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof, is administered once daily in a single dosing session to the patient.
Owner:INSMED INC +3

Lithium salt extended-release formulations; methods of making; and methods of use thereof

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.
Owner:ALMATICA PHARMA LLC

Modified release trazodone dosage forms

PCT designated stageWO2025179377A1Organic active ingredientsNervous disorderModified Release Dosage FormOral medication
The present disclosure is based on a surprising finding that a pH sensitive modified release dosage form is a suitable platform for trazodone therapy. Herein is described a pH sensitive modified release dosage form for once-a-day oral administration of trazodone, or a derivative thereof, comprising from 20% to 50% by weight of the trazodone or the derivative thereof, and from 10% to 80% of a release modifying excipient, which is a hydrogel-forming excipient. The present disclosure is also based on a surprising finding that dosage forms comprising trazodone have particular particle size distribution features that are advantageous for uniform release properties, even upon subdivision. In one such embodiment, less than 35% of the particles are 355μm to 500μm, greater than 5% of the particles are 250μm to 355μm, greater 2% of the particles are 75μm to 150μm, and greater than 5% of the particles are less than 38μm.
Owner:ALTUS FORMULATION INC

Formulations comprising triethylenetetramine tetrahydrochloride

This invention relates to pharmaceutical formulations comprising triethylenetetramine tetrahydrochloride (TETA.4HCl). Specifically, it relates to pharmaceutical compositions suitable for once-daily administration to subjects in therapeutic need.
Owner:ORPHALAN SA

Sustained-release injectable compositions comprising dutasteride

The present invention relates to a sustained-release injectable composition containing dutasteride, which can produce a sustained dutasteride release effect for more than 3 months even when the dosage of dutasteride administered is the same or lower than that of conventional once-daily Avodart®, thereby enabling a sustained drug administration effect for a long period of time with a single injection. In addition, it can continuously provide therapeutic effects for benign prostatic hyperplasia, prostate cancer, and hair loss for more than 3 months, and the microparticles included in the sustained-release injectable composition have a constant average diameter, so the release of the drug can be controlled to maintain a constant effective drug concentration, and the foreign body sensation and pain when administered to a patient as an injection can be reduced.
Owner:INVENTAGE LAB INC

Dosage regimens for AZD5004

The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment in a subject in need thereof.
Owner:ASTRAZENECA AB

Endoxifen citrate dosage guidelines for the treatment of bipolar I disorder

UndeterminedES3084585T3Bipolar type I disorderPharmaceutical drug
A method is provided for maintaining a therapeutically effective concentration of endoxifen for the treatment of a patient with bipolar I disorder. This method consists of administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric-coated tablet once daily for at least 21 days. Furthermore, rescue medication is not required during endoxifen citrate administration.
Owner:JINA PHARMACEUTICALS INC (100 00)

Methods of treating gastrointestinal diseases and disorders

Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.
Owner:CRISTCOT LLC